Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

MLN9708 (ixazomib citrate), which hydrolyzes to pharmacologically active MLN2238 (ixazomib), is a next-generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity, but yet with an unknown effect on myeloma bone disease. Here, we investigated its bone anabolic and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2014-03, Vol.20 (6), p.1542-1554
Hauptverfasser:	GARCIA-GOMEZ, Antonio, QUWAIDER, Dalia, GROEN, Richard W. J, MATEO-URDIALES, Joaquin, FRAILE, Susana, GALARRAGA, Miguel, CHAUHAN, Dharminder, SAN MIGUEL, Jesús F, RAJE, Noopur, GARAYOA, Mercedes, CANAVESE, Miriam, OCIO, Enrique M, ZE TIAN, BLANCO, Juan F, BERGER, Allison J, ORTIZ-DE-SOLORZANO, Carlos, HERNANDEZ-IGLESIAS, Teresa, MARTENS, Anton C. M
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic agents Antineoplastic Agents - pharmacology Biological and medical sciences Bone Resorption - metabolism Boron Compounds - pharmacology Cell Line Disease Models, Animal Diseases of the osteoarticular system Glycine - analogs & derivatives Glycine - pharmacology Hematologic and hematopoietic diseases Humans Immunoblotting Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Mesenchymal Stem Cells - drug effects Mesenchymal Stem Cells - metabolism Mice Mice, Inbred NOD Mice, SCID Multiple Myeloma - metabolism Osteoclasts - drug effects Osteoclasts - metabolism Osteoporosis. Osteomalacia. Paget disease Pharmacology. Drug treatments Proteasome Inhibitors - pharmacology Real-Time Polymerase Chain Reaction Reverse Transcriptase Polymerase Chain Reaction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!